A clinical trial to evaluate long-acting antiretroviral therapy (ART) for maintaining HIV suppression in people for whom adhering to conventional daily oral ART has been a challenge has begun at research sites across the United States. The study, called Long-Acting Therapy to Improve Treatment Success in Daily Life, or LATITUDE, will help determine whether a combination of two experimental injectable formulations of ART are superior to conventional oral ART in managing HIV infection in this population.
- Published
- 09 May 2019
- From
-
National Institute of Allergy and Infectious Diseases
If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV
- Published
- 29 April 2019
- From
-
ViiV press release
Recommendation based on landmark GEMINI 1 & 2 studies which demonstrated non-inferior efficacy of dolutegravir + lamivudine compared to a traditional dolutegravir-based, three-drug regimen, in HIV-1 infected, treatment-naïve adults.
- Published
- 26 April 2019
- From
- ViiV press release
Gilead Sciences wanted to represent the wide range of people living with HIV in its first national TV campaign for Biktarvy. So they chose black, Latino, male, female, gay, bisexual and transgender actors for an ad that encourages people with HIV to “keep being you.”
- Published
- 18 April 2019
- From
-
FiercePharma
Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens, according to a report published online today in The New England Journal of Medicine.
- Published
- 18 April 2019
- From
- NIAID
When HIV drugmaker ViiV announced in late 2017 that it had received Food and Drug Administration (FDA) approval for Juluca (dolutegravir/rilpivirine), the first effective two-drug, single-pill HIV regimen in the modern treatment era, community activists hoped that its price would reflect the fact that it contained one drug fewer than three-drug tablets like Complera (rilpivirine/tenofovir disoproxil fumarate/FTC), Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide), Stribild (cobicistat/elvitegravir/FTC/tenofovir disoproxil fumarate), and Triumeq (abacavir/dolutegravir/lamivudine), all of which are generally priced between $2,600 and $3,500 a month in the U.S.
- Published
- 15 April 2019
- From
-
The Body
The U.S. Food and Drug Administration today approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato. This is the first FDA-approved two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV.
- Published
- 09 April 2019
- From
-
Food & Drug Administration
New medicines providing a better quality of life should always be top priority when asking for federal support.
- Published
- 27 March 2019
- From
-
HivPlusMag.com
RBC Capital Markets analyst Brian Abrahams specifically mentioned a somewhat surprising reason to be excited about Gilead's prospects. He thinks that experimental HIV drug GS-6207 could be a transformative catalyst for Gilead. But GS-6207 is only in phase 1 clinical testing. It could take years for the drug to reach the market.
- Published
- 24 March 2019
- From
-
Motley Fool
Researchers followed a small group of people with highly drug-resistant virus taking Trogarzo (ibalizumab-uiyk) plus an optimized background regimen.
- Published
- 20 March 2019
- From
-
Poz
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...